维普期刊资源整合服务平台（V6.5）

241篇 您的检索式：作者名="Man RA"

选中清除导出查看参考文献查看引证文献引用追踪共13页首页上一页第1页下一页末页 /13 跳转

	题名	作者	年代	出处	被引量
1	Future prospectives for the management of chronic hepatitis B显示文摘Chronic hepatitis B virus infection affects about 400 million people around the globe and causes approximately one million deaths a year. Since the discovery of interferon-α as a therapeutic option the treatment of hepatitis B has evolved fast and management has become increasingly complicated. The amount of viral replication reflected in the viral load (HBV-DNA) plays an important role in the development of cirrhosis and hepatocellular carcinoma. The current treatment modalities for chronic hepatitis B are immunomodulatory (interferons) and antiviral suppressants (nucleoside and nucleotide analogues) all with their own advantages and limitations. An overview of the treatment efficacy for both immunomodulatory as antiviral compounds is provided in order to provide the clinician insight into the factors influencing treatment outcome. With nucleoside or nucleotide analogues suppression of viral replication by 5-7 log10 is feasible, but not all patients respond to therapy. Known factors influencing treatment outcome are viral load, ALT levels and compliance. Many other factors which might influence treatment are scarcely investigated. Identifying the factors associated with response might result in stopping rules, so treatment could be adapted in an early stage to provide adequate treatment and avoid the development of resistance. The efficacy of compounds for the treatment of mutant virus and the cross- resistance is largely unknown. However, genotypic and phenotypic testing as well as small clinical trials provided some data on efficacy in this population. Discontinuation of nucleoside or nucleotide analogues frequently results in viral relapse; however, some patients have a sustained response. Data on the risk factors for relapse are necessary in order to determine when treatment can be discontinued safely. In conclusion: chronic hepatitis B has become a treatable disease; however, much research is needed to tailor therapy to an individual patient, to predict the sustainability of response and determine thebest treatment for those failing treatment.	WF Leemans HLA Janssen RA de Man	2007	World Journal of Gastroenterology2007，13，18：	14
2	Histological improvement following administration of autologous bone marrow‐derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study显示文摘	Yoon Ok Jang Young Ju Kim Soon Koo Baik Moon Young Kim Young Woo Eom Mee Yon Cho Hong Jun Park So Yeon Park Bo Ra Kim Jae Woo Kim Hyun Soo Kim Sang Ok Kwon Eun Hee Choi Yong Man Kim	2014	Liver Int2014，，1：	2
3	Exacerbation of chronic hepatitis B infection after delivery显示文摘	Ter Borg MJ Leemans WF De Man RA	2008	Journal of Viral Hepatitis2008，15，1：	1
4	Multi-spectral molecular imagi-ng of capillaryendotheliumto facilitate preoperative endovascular br-ain mapping显示文摘	Manning HC Shay SD Mericle RA	2009	J Neurosurg2009，110，5：	1
5	A randomized study on the efficacy and safety of an automated Tru-Cut needle for pereutaneous liver biopsy显示文摘	De Man RA Van Buuren HR Hop WC	2004	Neth J Meal2004，62，：	1
6	Systematic review of haemorrhage and rupture of hepatocellular adenomas显示文摘	van Aalten SM de Man RA IJzermans JN	2012	Br J Surg2012，99，7：	1
7	Nucleoside analogues for chronic hepatitis B显示文摘	WOLTERS LM NIESTERS HG DE MAN RA	2001	Eur J Gastroenterol Hepatol2001，13，12：	1
8	Indications and long-term outcome of treatment of benign tumors: a criticalappraisall显示文摘	Terkivatan T de Wilt JH de Man RA	2001	Arch Surg2001，136，9：	1
9	A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance显示文摘	Manning AK Hivert MF Scott RA	2012	Nat Genet2012，44，6：	1
10	A genome-wide approach accounting for body mass index identifies genetic variants influen-cing fasting glycemic traits and insulin resistance显示文摘	Manning AK Hivert MF Scott RA	2012	Nat Genet2012，44，6：	1
11	Indications and long-term outcome of treatment for benign hepatic tumors:a critical appraisal显示文摘	de Wilt JH de Man RA	2001	Arch Surg2001，136，9：	1
12	Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays 显示文摘	Pas SD Fries E De Man RA	2000	J Clin Microbiol2000，38，8：	1
13	Entecavir:a potent new antiviral drug for hepatitis B显示文摘	De Man RA	2003	Expert Opin Investig Drugs2003，12，4：	1
14	Determinants of quality of life in chronic liver patients显示文摘	Gutteling J J de Man RA van der Plas SM	2006	Aliment Pharmacol Ther2006，23，11：	1
15	A potent new antiviral drug for hepatitis B显示文摘	HONKOOP P DE MAN RA	2003	Expert Opin Investig Drugs2003，12，：	1
16	Safety and efficacy of o ral entecavir given for 28 days in patients with chronic hepatitis B virus infection显示文摘	Wolters LM Nevens F	2001	Hepatology2001，34，3：	1
17	Histolog-ical improvement in patients withchronic hepatitis B virus infection treated with lamivudine显示文摘	Honkoop P De Man RA Zondervan PE	1997	Liver1997，17，2：	1
18	Histologicalimprovement in patients with chronic hepatitis B virusinfection trwated with lamivudine显示文摘	Honkoop P de Man RA Zondervan PE	1997	Liver1997，17，2：	1
19	Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy 显示文摘	Honkoop P de Man RA Niesters HG	2000	Hepatology2000，32，：	1
20	Development of a quantitative real-lime detection assay for hepatitis B virus DNA and comparison with two commericial assays显示文摘	Pas SD Fries E De Man RA	2000	J Clin Microbiol2000，38，：	1

返回顶部每页显示：

共13页首页上一页第1页下一页末页 /13 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示